Inhibition of breast adenocarcinoma growth by intratumoral injection of lipophilic long-acting lathyrogens

Anti-Cancer Drugs

Volumn 16, Issue 2, 2005, Pages 201-210

  Chvapil, Milos ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE   (United States)

Author keywords

Angiogenesis; Collagen structure; D penicillamine methyl and hexyl esters; Hexyl 3 (imino)propionitrile; Lathyrogen; Mammary adenocarcinoma tumor stability; Matrix metalloproteinases; Schiff base crosslinks

Indexed keywords

3 AMINOPROPIONITRILE; COLLAGEN FIBRIL; CYCLOPHOSPHAMIDE; LATHYROGEN DERIVATIVE; PENICILLAMINE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BREAST ADENOCARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; CROSS LINKING; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; FEMALE; LIPOPHILICITY; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; TUMOR REGRESSION;

ADENOCARCINOMA; AMINOPROPIONITRILE; ANIMALS; ANTINEOPLASTIC AGENTS; ESTERS; FEMALE; FIBRILLAR COLLAGENS; INJECTIONS, INTRALESIONAL; MAMMARY NEOPLASMS, ANIMAL; PENICILLAMINE; RATS;

EID: 13844272002     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200502000-00013     Document Type: Review

References (39)

1. Chvapil M. Pharmacology of fibrosis: definitions, limits and perspectives. Life Sci 1975; 16:1345-1362.
2. Chvapil M. Method of the treatment of fibrotic lesions by topical administration of lathyrogenic drugs. In: Nimni M (editor): Collagen, Vol. II, Biochemistry and Biomechanics. Boca Raton, FL: CRC Press; 1988, pp. 162-175.
3. Elkin M, Miao H, Nagler A, Aingom E, Reich R, Memo I, et al. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J 2000; 14:2477-2485.
4. Chvapil M. Method of treatment of fibrotic lesions by topical administration of lathyrogenic drugs. US Patent 4,485,088; 1984.
5. Ingber DE. Extracellular matrix and cell shape: potential control points for inhibition of angiogenesis. J Cell Biochem 1991; 47:236-241.
6. Dhom G. The cancer cell and the connective tissue. Pathology 1994; 15:271-278.
7. Heino J. Integrin-type extracellular matrix receptors in cancer and inflammation. Ann Med 1993; 25:335-342.
8. Inberg DE, Folkman J. How does extracellular matrix control capillary morphogenesis. Cell 1989; 58:803-805.
9. Korff T, Augustin HG. Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. J Cell Sci 1999; 19:3249-3258.
10. Meredith JE, Fazeli B, Schwartz MA. The extracellular matrix as cell survival factor. Mol Biol Cell 1993; 4:935-961.
11. Ingber DE. Extracellular matrix as a solid-state regulator in angiogenesis: identification of new targets for anti-cancer therapy. Semin Cancer Biol 1992; 3:57-63.
12. Sage EH, Vemon RB. Regulation of angiogenesis by ECM: the growth and the glue. J Hypertens Suppl 1994; 12:8145-8152.
13. Sipos EP, Tamargo RJ, Weingart JD, Brem H. Inhibition of tumor angiogenesis. Ann NY Acad Sci 1994; 732:263-272.
14. Ingber D, Folkman J. Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 1988; 59:44-51.
15. Bear HD, Kaplan AM, Cohen IK. Effects of BAPN-F on tumor growth and immune response. Surg Forum 1978; 29:137-139.
16. Diegelmann RF, Cohen IK. Elevated collagen synthesis in dimethylanthracene rat breast tumors and the effect of BAPN on tumor growth. Surg Forum 1978; 29:176-178.
17. Cohen IK, Moncure CW, Witorsch RJ, Diegelman RF. Collagen synthesis in capsules surrounding dimethylbenzathrene-induced rat breast tumor and the effect of pretreatment with BAPN. Cancer Res 1979; 39:2923-2927.
18. Bankowski E, Sobolewski K, Jodczyk KJ. Effect of lathyrogen on collagen of methylchlanthrene-induced sarcoma in rat. Zentralbl Allg Pathol 1990; 136:247-253.
19. Ogata M, Kida K, Noda K. Changes in alveolar capillary formation in growing rat lung by repeated injections of a lathyrogen. Growth Dev Aging 1996; 60:153-162.
20. Brem S. Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control 1999; 5:436-458.
21. Knight KR, Gibbons R. Increased collagen synthesis and cross-link formation in the skin of rats exposed to vinyl chloride monomer. Clin Sci (Colch) 1987; 72:673-678.
22. Nimni NI. A defect in the intermolecular and intramolecular cross-linking of collagen caused by penicillamine. J Biol Chem 1968; 243:1457-1466.
23. Nimni ME. Penicillamine and collagen metabolism. Scand J Rheumatol Suppl 1979; 28:71-78.
24. Harkness RD, Nimni ME. Chemical and mechanical changes in the collagenous framework of skin induced by thiol compounds. Acta Physiol Acad Sci Hung 1968; 33:325-343.
25. Hourani BT, Demopoulos HB. Inhibition of S-91 mouse melanoma metastases and growth by DPA. Lab Invest 1969; 21:434-438.
26. Okuyama S, Mishina H. Probable Superoxide therapy of experimental cancer with DPA. Tohoku J Exp Med 1981; 135:215-216.
27. Jong-Hong K, Togashi Y, Kasai H, Hosokawa M, Takeishi N. Prevention of spontaneous hepatocellular carcinoma in Long-Evans cinnamon rats with hereditary hepatitis by the administration of DPA. Hepatology 1993; 18:614-620.
28. Brem S, Tsanaclis AM, Zagzag D. Anticopper treatment inhibits pseudopodial protrusion and the invasive spread of 9L gliosarcoma cells in the rat brain. Neurosurgery 1990; 26:391-396.
29. Camphausen K, Sproull M, Tantama S, Sankineni S, Scott T, Menard C, et al. Evaluation of copper chelation agents as anti-angiogenic therapy. Bioorg Med Chem 2003; 11:4287-4293.
30. Yoshida D, Ikeda Y, Nakazawa S. Copper chelation inhibits tumor angiogenesis in the experimental 9L gliosarcoma model. Neurosurgery 1995; 37:287-292.
31. Miller EE, Evans AE, Cohn M. Inhibition of rate of tumor growth by creatine and cyclocreatine. Proc Natl Acad Sci USA 1993; 90:3304-3308.
32. Chvapil M, Speer D, Owen JT, Chvapil T. Identification of the depth of burn injury by collagen stainability. Plastic Reconstruct Surg 1984; 73:438-441.
33. Genovese RL, Rantanen NW, Simpson BS, Simpson DM. Clinical experience with quantitative analysis of superficial flexor tendon injuries in Thoroughbred and Standardbred race horses. Vet Clin Natl An Equine Pract 1990; 1:29-45.
34. Speer DP, Feldman S, Chvapil M. The control of peritendinous adhesions using topical BAPN base. J Surg Res 1985; 38:252-257.
35. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, et al. The mechanism of cancer mediated of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 1997; 94:10868-10872.
36. van Golen KL, Bao L, Brewer GJ, Pienta KJ, Kamradt JM, Livant DL, et al. Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate cancer. Neoplasia 2002; 4:373-379.
37. Brewer GJ, Merajver SD. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper-a review. Integr Cancer Ther 2002; 1:327-237.
38. Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 1992; 369:15-26.
39. Shian SG, Kao YR, Wu FY, Wu CW. Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram. Mol Pharmacol 2003; 64:1076-1084.